PPIDT00049
Drug Information
| Name | Gemtuzumab ozogamicin |
|---|---|
| Sequence | DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
| DrugBank_ID | DB00056 |
| Type | biotech |
| Indication | Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous |
5 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
5 mg/5mL
|
| Powder, for solution | Intravenous |
4.5 mg / vial
|
| Powder, for solution | Intravenous |
5.0 mg
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P20138 | CD33 | Myeloid cell surface antigen CD33 | Homo sapiens | antibody|regulator | Link |
| target | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | Homo sapiens | unknown | Link |
| target | P08637 | FCGR3A | Low affinity immunoglobulin gamma Fc region receptor III-A | Homo sapiens | unknown | Link |
| target | P12314 | FCGR1A | High affinity immunoglobulin gamma Fc receptor I | Homo sapiens | unknown | Link |